Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's Disease

13Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. We aimed to identify certain genes related to response to infliximab (IFX) and biomarkers to predict the IFX effect for Japanese Crohn's disease (CD) patients by performing an association study of single nucleotide polymorphisms (SNPs) in candidate genes in the interleukin-(IL-) 17 signaling pathway with response to IFX after 1 year of treatment. Methods. A total of 103 patients were divided into two groups, responders and nonresponders. Twenty-eight tag SNPs in 5 genes were genotyped. The frequencies of alleles and genotypes of each SNP were compared between responders and nonresponders in three different inheritance models. A genetic test was performed using a combination of the associated SNPs as biomarkers. Results. Multivariate logistic regression analysis indicated that the four variable factors, concomitant use of immunomodulators, penetrating disease, a G/G genotype of rs766748 in IL-17F, and a C/C or C/A genotype of rs1883136 in TRAF3IP2, independently contributed to response to IFX after 1 year of treatment. Genetic test using the polymorphisms of these genes perfectly predicted the responder and nonresponder CD patients with both concomitant use of immunomodulators and penetrating disease. Conclusion. IL17F and TRAF3IP2 are one of IFX-related genes, useful as biomarkers of IFX response, and may be target molecules for new therapeutic drugs.

References Powered by Scopus

Haploview: Analysis and visualization of LD and haplotype maps

12710Citations
N/AReaders
Get full text

A haplotype map of the human genome

4916Citations
N/AReaders
Get full text

Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial

3920Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients with Inflammatory Bowel Disease: From Basic Science to Clinical Practice

195Citations
N/AReaders
Get full text

Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 genes are associated with the response to TNF inhibitors in patients with rheumatoid arthritis

26Citations
N/AReaders
Get full text

Pharmacogenetics of biological agents used in inflammatory bowel disease: A systematic review

25Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Urabe, S., Isomoto, H., Ishida, T., Maeda, K., Inamine, T., Kondo, S., … Tsukamoto, K. (2015). Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease. BioMed Research International, 2015. https://doi.org/10.1155/2015/416838

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

61%

Researcher 4

22%

Professor / Associate Prof. 2

11%

Lecturer / Post doc 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

53%

Pharmacology, Toxicology and Pharmaceut... 4

21%

Biochemistry, Genetics and Molecular Bi... 3

16%

Agricultural and Biological Sciences 2

11%

Save time finding and organizing research with Mendeley

Sign up for free